Felix Baker
CIK 1087940 · last filed 2026-09-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
860 WASHINGTON STREET 3RD FLOOR
NEW YORK, NY 10014
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KOD | Director | 18,852,329 | $89.96 | $1.70B | $787.86M | 6 | 2026-09-30 |
| CELC | 442,940 | $68.21 | $30.21M | -$1.27B | 1 | 2026-07-16 | |
| INCY | Director | 3,115,871 | $116.06 | $361.63M | -$15.68M | 30 | 2026-06-10 |
| KNSA | Director | 2,759,734 | $89.66 | $247.44M | $324.00M | 4 | 2026-06-02 |
| VTVT | Director | 12,368 | $25.65 | $317.2K | $0 | 2 | 2025-09-05 |
| MDGL | Director | 1,796,261 | $439.05 | $788.65M | $0 | 2 | 2025-06-24 |
| DBVT | Director | — | $10.11 | — | $0 | 1 | 2025-03-31 |
| ONC | Director | 730,643 | $364.56 | $266.36M | -$1.14B | 1 | 2025-02-28 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 3,123,770 | $1.27 | $3.97M | $20.59M | 2 | 2024-03-14 |
| Neurogene Inc. (NLTX) Delisted | Director | 39,081 | $13.96 | $545.6K | $38.80M | 3 | 2023-10-10 |
| TRDA | 10%+ Owner | 360,122 | $4.37 | $1.57M | $2.77M | 2 | 2022-06-06 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 470,212 | $2.84 | $1.34M | $1.31M | 1 | 2021-11-19 |
| Seagen Inc. (SGEN) Delisted | Director | 4,124,966 | $228.74 | $943.54M | $2.56B | 33 | 2021-05-18 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 18,590 | $184.71 | $3.43M | -$160.29M | 1 | 2021-01-06 |
| PRLD | Director | 9,247,763 | $3.86 | $35.70M | $180.00M | 1 | 2020-09-30 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | — | $0.15 | — | $0 | 1 | 2020-07-20 |
| Neurogene Inc. (AQXP) Delisted | Director | 1,178,742 | — | — | $6.69M | 1 | 2019-08-08 |
| Aceragen, Inc. (IDRA) Delisted | Director | 5,249 | $7.22 | $37.9K | -$20.91M | 14 | 2019-04-03 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 185,836 | — | — | -$232.16M | 49 | 2019-03-19 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 3,054,192 | $58.70 | $179.28M | $0 | 1 | 2016-04-01 |
| BCRX | 10%+ Owner | 2,145,586 | $8.04 | $17.25M | $7.12M | 7 | 2016-02-09 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 50,111 | — | — | $270.67M | 14 | 2015-06-22 |
| ACAD | Director | 1,468,014 | $20.18 | $29.62M | $201.38M | 3 | 2013-06-11 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 116,454 | — | — | $93.93M | 18 | 2012-02-03 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 9,840,469 | — | — | $219.64M | 22 | 2011-12-16 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 72,731 | — | — | -$7.68M | 5 | 2011-08-03 |
| RPRX | 10%+ Owner | 1,608,196 | $65.00 | $104.53M | $4.61M | 2 | 2010-06-02 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 83,205 | — | — | $14.68M | 15 | 2009-02-06 |
| NEUROGEN CORP (NRGN) Delisted | Director | 690,856 | — | — | $0 | 12 | 2008-11-13 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 41,120 | — | — | -$173 | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 502,680 | — | — | -$7.15M | 10 | 2007-12-07 |
Recent Filings · Page 13 of 30
292 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-07-05 | GENOMIC HEALTH INC (GHDX) Delisted | Other (J) | −21,840 | $0 | EDGAR |
| 2011-07-05 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Other (J) | −20,976 | $0 | EDGAR |
| 2011-07-05 | Seagen Inc. (SGEN) Delisted | Other (J) | +32,298 | $0 | EDGAR |
| 2011-07-05 | — | Other (J) | +8,706 | $0 | |
| 2011-05-20 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-04-26 | — | Buy (P) | — | $0 | |
| 2011-04-26 | — | Buy (P) | — | $0 | |
| 2011-03-31 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Buy (P) | +996,000 | $21.89M | EDGAR |
| 2011-03-11 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +212,568 | $5.53M | EDGAR |
| 2011-03-08 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +1,048,698 | $26.28M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.